Appendix 1: NHS Lothian approved DOACs - pharmacological information
Acute Oncology Guidelines
Warning
NHS Lothian approved DOACs - pharmacological information 8,43,44
| Apixaban | Edoxaban | Rivaroxaban | |
| Target | Factor Xa | Factor Xa | Factor Xa |
| Oral bioavailability | 50% | 62% | 60-80% |
| Peak blood levels | 3-4h | 1-2h | 2-4h |
| Half-life | 8-15h | 10-14h |
5-9h healthy 11-13h elderly |
| Administration | BD | OD | OD or BD |
| Metabolism/elimination |
25% renal 75% biliary |
35% renal 65% biliary |
66% renal 33% biliary |
| LFC-approved indications |
Treatment of acute DVT or PE Prevention of recurrent DVT or PE Prophylaxis of stroke and prevention of systemic embolism in non-valvular atrial fibrillation - moderate and high risk (age >65 years or <65 years and any additional stroke risk factors) |
Treatment of acute DVT or PE Prevention of recurrent DVT or PE |
Prophylaxis of venous thromboembolism following elective total hip or knee replacement |
|
To guide prescribers NHS Lothian has created 'Ambulatory Care DVT & PE Pathways' and 'Apixaban Prescribing Guidance Prescriber Information' which can be found on the Haematology intranet site (Policies) |
|||